Bottom line
What is NDVAX's expense ratio?
NDVAX's expense ratio is 1.22%, or about $122 a year on every $10,000 invested. That is more expensive than 79% of large value funds we track (median 0.81%). This share class also charges a front-end sales load of up to 5.75%, taken from your investment when you buy. Its expense ratio includes a 0.25% 12b-1 marketing fee.
Updated Jun 25, 2026
NDVAX fee table
| Net expense ratio | 1.22% |
|---|---|
| Gross expense ratio | 1.23% |
| Management fee | 0.83% |
| 12b-1 (distribution) fee | 0.25% |
| Other expenses | 0.15% |
| Fee waiver / reimbursement | -0.01% |
| Max front-end sales load | 5.75% |
| Max deferred sales charge | 1% |
Source: Fund prospectus fee table, filed Jun 25, 2026
What NDVAX costs in dollars
The SEC requires every fund to show what a $10,000 investment would cost, assuming 5% annual returns and that you sell at the end of each period:
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| NDVAX | $692 | $942 | $1,211 | $1,977 |
Source: Fund prospectus expense example
The long-run cost of fees
On $100,000 growing at 6% a year for 20 years, a 1.22% expense ratio costs roughly $66,300 in lost growth, versus about $45,600 for the median large value fund (0.81%).